IMAGING SCIENCE AND PHOTOCHEMISTRY ›› 2022, Vol. 40 ›› Issue (5): 1174-1178.DOI: 10.7517/issn.1674-0475.220409

• Review and Articles • Previous Articles     Next Articles

Effects of Bendamustine Combined with Ixazomib on sVCAM-1, β2-MG and Ultrasound Parameters in MM Patients

LIU Min, YU Zhuojun, LIANG Yan, HUANG Zhiping, TANG Yuanyan   

  1. Department of Hematology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou 434020, Hubei, P. R. China
  • Received:2022-04-26 Published:2022-09-13

Abstract: This paper exploreed the value of bendamustine combined with ixazomib for sVCAM-1 and β2-MG in patients with multiple myeloma (MM). Selected 100 multiple myeloma patients as research subjects, and divided them into the control group with 50 patients and 50 patients in the study group randomly. Both the two groups were given symptomatic treatment, the control group received dexamethasone plus bendamustine, and the study group gave dexamethasone plus bendamustine plus ixazomib. Before and after treatment, the patients in both groups were examined by ultrasound, the sVCAM-1 and β2-MG levels were tested as well. After treatment, the sVCAM-1, β2-MG, cortical IBS, medulla IBS, interlobe artery RI levels decreased, and the study group was lower than the control group. The kidney volume, kidney length, interlobe artery PSV levels increased, and the study group was higher than the control group (P<0.05). Compared with the ineffective patients in the study group, the effective patients had higher levels of kidney volume, kidney length, and interlobar artery PSV, while lower cortical IBS, medulla IBS, and interlobar artery RI levels (P<0.05). The effective rate of treatment in the study group was significantly higher than that in the control group (P<0.05). To sum up, the levels of sVCAM-1 and β2-MG in patients with multiple myeloma decreased after bendamustine combined with ixazomib treatment, and the clinical efficacy was satisfactory, and the ultrasound parameters changed significantly after the combined treatment, which suggested that ultrasound can be used for evaluation of clinical efficacy in patients with multiple myeloma.

Key words: multiple myeloma, ixazomib, bendamustine, soluble vascular cell adhesion molecule-1, β2-microglobulin, ultrasound